Advertisement

Topics

Janssen, Adaptive to Develop clonoSEQ for Measuring MRD in Darzalex-Treated MM

06:06 EDT 21 Jun 2017 | Genetic Engineering News

Janssen Biotech and Adaptive Biotechnologies established a collaboration to develop the latter’s next-generation sequencing (NGS)-based clonoSEQ® Assay for measuring minimal residual disease (MRD) in multiple myeloma (MM) patients treated using Janssen’s Darzalex (daratumumab). Darzalex is a CD38-targeting antibody approved for treating relapsed or refractory MM.  Janssen will pay Adaptive an undisclosed upfront technology access payment, plus development funding and potential future milestone payments. The partners aim to demonstrate the clinical utility of the clonoSEQ assay for monitoring MRD negativity in MM patients, and will also assess the drug’s ability to achieve MRD. Adaptive will be responsible for pursuing regulatory approval of and commercializing the clonoSEQ Assay in MM.   “Adaptive is thrilled to develop the technology to help measure the depth of response generated by Darzalex in patients with MM,“ said Chad Robins, CEO and cofounder of Adaptive Biotechnologies. “We look forward to advancing our strategic partnership with ...

Original Article: Janssen, Adaptive to Develop clonoSEQ for Measuring MRD in Darzalex-Treated MM

NEXT ARTICLE

More From BioPortfolio on "Janssen, Adaptive to Develop clonoSEQ for Measuring MRD in Darzalex-Treated MM"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biotechnology - Biotech
"using living things to create products or to do tasks for humans" About Biotechnology - Biotech Biotechnology is the practice of using plants, animals and micro-organisms such as bacteria, as well as biological processes - such as the ripen...

Biotechnology
Antibodies Antisense Assays Biochips Bioinformatics Biological Therapy Biomarkers Biomaterials Bioscience Cell Culture Cloning Cytokine Diagnostics Dna Extraction Dna Sequencing Dna Transform...

Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...